Navigation Links
MU researchers find unique protein organization in arteries associated with cardiovascular disease
Date:1/9/2012

COLUMBIA, Mo. Human arteries some smaller than a strand of hair stiffen as a person ages. This stiffening is a factor in cardiovascular disease, the leading cause of death in the United States, because it contributes to the circulatory complications in disorders such as high blood pressure and diabetes. University of Missouri researchers have now used advanced 3-D microscopic imaging technology to identify and monitor the proteins involved in this stiffening process. These findings could eventually help researchers and physicians understand and treat complications associated with cardiovascular disease.

"A majority of the scientific knowledge of how blood vessels are put together is based on older methodologies that only measured the amount of protein in the artery wall and not how the proteins were architecturally arranged to support artery functions," said Gerald Meininger, director of the MU Dalton Cardiovascular Research Center and Margaret Proctor Mulligan Professor of Medical Pharmacology and Physiology. "We used state-of-the-art imaging technology and computer-based models to visualize the minute structural elements within an intact blood vessel and found that one of the proteins, elastin, plays a key role in supporting the ability of the arterial wall to properly function."

As people age, the level of elastin diminishes and other proteins, such as collagen, contribute to altering the arterial stiffness. The researchers believe that learning how to alter elastin levels may alleviate some of the detrimental results associated with vascular aging, such as high blood pressure.

"When people think of blood vessels, they tend to think of rigid pipes, but blood vessels are very dynamic because they continually expand and contract to adjust blood flow and blood pressure to meet the body's needs," said Michael Hill, also of the Dalton Cardiovascular Research Center and Professor of Medical Pharmacology and Physiology. "Elastin production peaks at a very young age and declines throughout life. Molecular biologists are trying to determine how to turn elastin production back on in the correct places, but it has proven very difficult so far."

The MU researchers believe the knowledge also may be used in future efforts to develop artificial vascular structures to improve tissue replacement. Blood vessels sometimes fail during the tissue replacement process, and understanding how vessels are built and change could lead to a better success rate.

The study, "Spatial Distribution and Mechanical Function of Elastin in Resistance Arteries," was published in Arteriosclerosis, Thrombosis, and Vascular Biology, the Journal of the American Heart Association. The study was funded by the National Institutes of Health.


'/>"/>

Contact: Steven Adams
AdamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert  

Related biology news :

1. Frogs use calls to find mates with matching chromosomes, University of Missouri researchers find
2. Viagra against heart failure: Researchers at the RUB and from Rochester throw light on the mechanism
3. DOE researchers achieve important genetic breakthroughs to help develop cheaper biofuels
4. Drugs used to overcome cancer may also combat antibiotic resistance: McMaster researchers
5. Researchers develop new method of cleaning toxins from the oilsands
6. Researchers discover a way to significantly reduce the production costs of fuel cells
7. San Diego Zoo researchers contribute to project using mummy DNA to differentiate croc species
8. Researchers create living neon signs composed of millions of glowing bacteria
9. Georgetown researchers lead discovery expected to significantly change biomedical research
10. 4 UC Riverside researchers receive national recognition
11. Researchers assess effects of a world awash in nitrogen
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MU researchers find unique protein organization in arteries associated with cardiovascular disease
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017  Market Research Future has a half cooked research report ... is growing rapidly and expected to reach USD 450 Million by ... ... Market has been assessed as a swiftly growing market and expected ... the coming future. There has been a tremendous growth in the ...
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... ... January 19, 2017 , ... Genedata, ... (R&D), today announced the launch of Data Science Services , offering ... evolving field of precision medicine. , Data Science Services allows pharmaceutical ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
Breaking Biology Technology: